10 November 2026. Hologen today announced the appointment of Jacopo Andreose, PhD, as Chief Biopharma Officer of Hologen and Chief Executive Officer of Reogen, its neural reprogramming gene therapy company.
At Hologen, Jacopo will join the leadership team and bring his depth of experience to the wider pharmaceutical and biotech programme. Hologen is developing Large Medicine Models trained on real-world clinical data. Bringing a new medicine to patients is slow, costly and uncertain. About nine in ten drugs that enter clinical trials never reach the market. Hologen was established to help change that. It can read clinical records and other heterogeneous patient data sources in far more depth, which helps teams choose the right patient populations, plan better-designed clinical trials and de-risk programmes earlier.
At Reogen, Jacopo will lead the team developing novel treatments for brain disorders. Its lead programme is an investigational gene therapy for Parkinson's disease, which has received Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA. Reogen is a joint venture formed by Hologen and MeiraGTx.
"Medicine has long been written in simple averages, but every patient is a sentence of their own," said Roland Tegeder, Chief Executive Officer of Hologen. "Our work is to learn the grammar of biology well enough to read each one. Jacopo has spent three decades turning science into medicines that reach people. At Hologen, he will help our partners put our model to work. At Reogen, he will lead a new kind of therapy for Parkinson's. We could not ask for a better person to carry both."
Jacopo has spent three decades in the pharmaceutical industry. He was most recently Chief Executive Officer of Angelini Pharma, where he led the company's transformation into a leader in brain health through R&D, business development and commercialisation efforts. Before that he was Senior Vice President for Intercontinental Region and Global Patient Solutions at Gilead Sciences, where he was responsible for the business across diverse geographies and therapeutic areas. Earlier roles at GSK, ViiV Healthcare, Bristol Myers Squibb and Abbott took him across the United States, the United Kingdom, Europe and Asia. He has led launches of new medicines in immunology, oncology, virology and neuroscience. He holds a PhD in pharmacology and completed a postdoctoral fellowship at Yale School of Medicine.
"I have spent my career getting medicines to patients, and I know how much time and certainty are lost along the way," said Jacopo Andreose. "Hologen and Reogen are two answers to that. Hologen's technology is trained on real clinical data and reads biology in a way that has not been possible before. Reogen has a chance to bring new hope to people living with Parkinson's disease. I am excited to get started."
About Hologen
Hologen builds AI models designed to guide clinical action, rather than simply make predictions, and uses them to create new ways of diagnosing, treating and preventing disease, including through its own clinical programmes. Drawing on high-dimensional, real-world biomedical data, its multimodal Large Medicine Models illuminate human biology and identify effective treatments, with individual-level precision. The company applies its models across diagnostics, therapeutics and health systems, working with technology, pharmaceutical and healthcare partners.